PDPN

Across TCGA pan-cancer cohorts, PDPN mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PDPN data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PDPN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PDPN expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, GBM, and LSCC are the cancer types where PDPN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.217	0.676	.017	3	view →
GBM	DFS	Quartile	All	0.709	0.882	.039	1	view →
LSCC	DFS	Median	II,III,IV	1.000	0.795	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PDPN–PDAC (DFS)

Open the PDAC breakdown →